The Role of Beta Cell Recovery in Type 2 Diabetes Remission.
Mara SuleimanLorella MarselliMiriam CnopDecio L EizirikCarmela De LucaFrancesca R FemiaMarta TesiSilvia Del GuerraPiero MarchettiPublished in: International journal of molecular sciences (2022)
Type 2 diabetes (T2D) has been considered a relentlessly worsening disease, due to the progressive deterioration of the pancreatic beta cell functional mass. Recent evidence indicates, however, that remission of T2D may occur in variable proportions of patients after specific treatments that are associated with recovery of beta cell function. Here we review the available information on the recovery of beta cells in (a) non-diabetic individuals previously exposed to metabolic stress; (b) T2D patients following low-calorie diets, pharmacological therapies or bariatric surgery; (c) human islets isolated from non-diabetic organ donors that recover from "lipo-glucotoxic" conditions; and (d) human islets isolated from T2D organ donors and exposed to specific treatments. The improvement of insulin secretion reported by these studies and the associated molecular traits unveil the possibility to promote T2D remission by directly targeting pancreatic beta cells.
Keyphrases
- type diabetes
- end stage renal disease
- bariatric surgery
- ejection fraction
- induced apoptosis
- newly diagnosed
- weight loss
- endothelial cells
- chronic kidney disease
- single cell
- prognostic factors
- peritoneal dialysis
- disease activity
- gene expression
- healthcare
- stem cells
- metabolic syndrome
- systemic lupus erythematosus
- drug delivery
- adipose tissue
- oxidative stress
- ulcerative colitis
- endoplasmic reticulum stress
- insulin resistance
- skeletal muscle
- mesenchymal stem cells
- obese patients
- cancer therapy
- stress induced
- induced pluripotent stem cells
- case control